bioAffinity Technologies, Inc. (BIAFW) Stock Price, Financials & Summary

Price chart

Oct 2Oct 7Oct 12Oct 16Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.24

From 52W high−65.03%

Volume0.00

Market cap$261042.48

P/E (TTM)—

P/S (TTM)0.0x

Div yield—

Key dataNov 4, 2026

Open

$0.24

From 52W high

−65.03%

Volume

0.00

Market cap

$261042.48

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.0x

P/E (TTM)

—

RSI (14)

47.7

MomentumView details →

1D Return

+0.00%

YTD Return

−30.06%

SummaryUpdated Jun 1, 2026

bioAffinity Technologies, Inc. (NASDAQ:BIAF) is a biotechnology company founded in 2014 and based in San Antonio, Texas. The company went public in September 2022 and specializes in developing non-invasive diagnostic tests and targeted cancer therapeutics. bioAffinity Technologies operates in the medical diagnostics and research sector, focusing primarily on early detection of lung cancer through innovative testing methods and researching targeted therapies to treat cancer at the cellular level.

Ask drillr about bioAffinity Technologies, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.0x

EV/Sales

−0.1x

P/S (TTM)

0.0x

P/B (TTM)

0.1x

ProfitabilityView details →

Gross Margin

−39.57%

Net Margin

−257.33%

EBITDA Margin

−249.47%

ROE (TTM)

−402.92%

ROA (TTM)

−199.30%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

−23.17%

EPS YoY

−30.67%

FCF YoY

−48.40%

Revenue CAGR 3Y

+986.60%

EPS CAGR 3Y

+61.51%

EBITDA YoY

−33.79%

MomentumView details →

1D Return

+0.00%

YTD Return

−30.06%

1Y Return

−38.80%

RSI (14)

47.7

vs 50D SMA

−18.16%

vs 200D SMA

−11.98%

Capital & dividendView details →

Debt/Equity

0.38x

Current Ratio

1.44x

Quick Ratio

1.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.64

EPS Surprise

69.52%

Beats (12Q)

3/12

Next Q EPS Est

−$27.00

Avg Surprise (4Q)

38.68%

Rev Surprise

−11.19%

Financials snapshotView financials →

Revenue (TTM)

5.90M

Net Income (TTM)

−15.19M

Op. CF (TTM)

−11.47M

Next earningsNov 18, 2026 →

Latest newsMore news →

bioAffinity Technologies appointed WallachBeth Capital LLC as exclusive placement agent on a best-efforts basis for the offering.26d ago

bioAffinity Technologies entered into a securities purchase agreement to sell 116,545 common shares and pre-funded warrants for 536,836 shares, and issued warrants for 980,072 shares in a private placement expected to generate approximately $4 million in gross proceeds.26d ago

Similar companies

Prenetics Global LimitedPRENW iSpecimen Inc.ISPC BioNexus Gene Lab Corp.BGLC Inotiv, Inc.NOTV Aspira Women's Health Inc.AWH Advanced Biomed Inc. Common StockADVB Find similar companies →

Latest newsMore news →

bioAffinity Technologies appointed WallachBeth Capital LLC as exclusive placement agent on a best-efforts basis for the offering.26d ago bioAffinity Technologies entered into a securities purchase agreement to sell 116,545 common shares and pre-funded warrants for 536,836 shares, and issued warrants for 980,072 shares in a private placement expected to generate approximately $4 million in gross proceeds.26d ago bioAffinity Technologies, Inc. announced that it received notice of allowance for a Japanese patent covering its noninvasive CyPath Lung diagnostic test and AI-built algorithm.27d ago